Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-15 activated allogeneic NK cells
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-15 activated allogeneic NK cells is an investigational adoptive cell therapy developed by Leiden University Medical Center (LUMC). The therapy involves natural killer (NK) cells harvested from an allogeneic donor, typically the same individual who provided stem cells for a prior hematopoietic stem cell transplant. These NK cells are activated ex vivo using interleukin-15 (IL-15), a cytokine that significantly enhances their survival, proliferation, and cytotoxic potential. Once infused into the patient, these activated NK cells target and eliminate malignant leukemic blasts by recognizing the absence of self-MHC class I molecules and through various germline-encoded activating receptors. The therapy is currently being evaluated in feasibility studies for pediatric patients with relapsed or refractory leukemia following allogeneic stem cell transplantation to determine its safety and potential efficacy in preventing or treating relapse.
- Other names
- interleukin-15 activated allogeneic natural killer cellsinterleukin15 activated allogeneic natural killer cellsinterleukin 15 activated allogeneic natural killer cellsIL-15 activated NK cellsIL15 activated NK cellsIL 15 activated NK cells
02
Targets
NECTIN1 (Poliovirus receptor-related 1)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on IL-15 activated allogeneic NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-15 activated allogeneic NK cells.